Is Bristol Myers Squibb Stock a Buy?

It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following the loss of patent exclusivity of two important medicines in its arsenal: cancer drugs Revlimid (its former top-selling product) and Abraxane. Bristol Myers has rebounded. Its revenue is moving in the right direction again. However, there will be more patent cliffs for the company in the near future.Can the drugmaker still deliver strong returns? Let's take a closer look.In September, generics for Bristol Myers' cancer medicine Sprycel entered the market. It isn't the company's most important product, not by a mile. However, the two medicines that carry that title -- Eliquis and Opdivo -- will face the same issue later this decade. Eliquis, an anticoagulant, will be out of patent exclusivity by 2029 at the latest, while Opdivo's cliff should come in 2028.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool